Table 12.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Lung Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		674	738	893	836	946	893	920	977	1,083	1,054
Tx with Antirejection Treatments		379	388	475	381	419	402	394	432	500	427
Antibodies	Category Usage	14.2%	17.8%	9.5%	10.8%	11.7%	15.9%	16.2%	18.8%	11.4%	13.6%
	ALG	0.3%	1.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	5.3%	10.6%	5.7%	7.3%	7.9%	10.9%	8.1%	7.4%	4.2%	3.3%
	OKT3	9.5%	7.7%	4.2%	3.7%	4.3%	3.2%	3.0%	2.5%	1.4%	2.1%
	Thymoglobulin	0.0%	0.0%	0.2%	0.0%	0.0%	0.7%	5.1%	5.8%	6.0%	4.9%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.2%	2.2%	1.0%	3.0%	0.8%	5.2%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.8%	2.8%	0.6%	0.2%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%
Corticosteroids	Category Usage	91.0%	92.5%	93.7%	90.0%	94.0%	91.5%	92.9%	88.2%	92.4%	94.8%
	Steroids	91.0%	92.5%	93.7%	90.0%	94.0%	91.5%	92.9%	88.2%	92.4%	94.8%
Antimetabolites	Category Usage	4.5%	3.1%	1.1%	5.0%	1.9%	0.7%	1.5%	1.2%	1.2%	0.2%
	Cytoxan	0.0%	0.8%	0.0%	0.8%	0.5%	0.2%	0.8%	0.5%	0.2%	0.2%
	Methotrexate	4.5%	2.3%	1.1%	4.2%	1.4%	0.5%	1.5%	0.7%	1.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.